Pharmafile Logo

Depression

- PMLiVE

Janssen submits esketamine in Europe for treatment resistant depression

Fast-acting drug would be first new treatment for refractory disease in 50 years

- PMLiVE

Sage surges after depression drug gets rapid path to approval

Will be able to file a marketing application based on its phase II trial

- PMLiVE

Aptar Pharma advances digital offerings

Partners up with digital therapeutics company Propeller Health

- PMLiVE

FDA looks to regulate digital tools

US regulator adds new components to digital health plan

Takeda explores the potential of ‘digital biomarkers’

Collaborates with Mindstrong Health on mental health research

Novartis plans digital therapeutics for schizophrenia and MS

Will work with Pear Therapeutics on a prescription software range

- PMLiVE

NICE backs trial of online and mobile depression programme

First digital psychological therapy briefing covers Servier and Gaia's Deprexis

New alliance launches to usher digital therapeutics into the mainstream

The Digital Therapeutics Alliance’s founding members include Akili and Voluntis

- PMLiVE

Akili to submit video game ADHD treatment for US approval in 2018

Follows trial suggesting attention benefits of its 'digital medicine' AKL-T01

Mental health in the workplace

Mental health in the workplace

One in five people in the workplace will experience a mental health condition. Learn to spot the signs and the steps that you can take to care for yourself and...

Porterhouse Medical Group

FDA approves first substance use mobile medical application

Pear Therapeutics' Reset device offers cognitive behavioural therapy

- PMLiVE

Could ketamine be the next big thing in depression?

Account Executive Will Frostick discusses the established treatment model for depression and its limitations, as well as a new entrant poised to revolutionise the field – ketamine.

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links